Aurobindo Pharma Limited
AUROPHARMA · Pharma · NSE
₹1,376
Current Market Price
Fair Value (DCF)
₹1,875
Margin of Safety
+36.3%
Updated 5h ago
YieldIQ Score
59/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
45%
ROE
10.7%
Debt/Equity
0.00
WACC
11.0%
Market Cap
₹0.80 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
15.7%
Return on capital employed
EV / EBITDA
11.6×
Enterprise multiple
Debt / EBITDA
1.2×
Leverage vs earnings
Interest Coverage
12.5×
EBIT covers interest
Current Ratio
1.85×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
15.6%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,376
Bear case
₹1,133.15
MoS -21.4%
Base case
₹1,875.02
MoS +26.6%
Bull case
₹2,516.16
MoS +45.3%
Ratio Trends
AUROPHARMA · last 7 annual periods
ROE
10.7%
ROCE
17.4%
Operating Margin
—
Debt / Equity
0.25×
PE
59.5×
EV / EBITDA
7.5×
Historical Financials
AUROPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹15.8K Cr | ₹23.5K Cr | ₹6473 Cr | ₹7580 Cr | ₹31.4K Cr | +18.7% |
| EBITDA | — | ₹4536 Cr | ₹3986 Cr | ₹6140 Cr | ₹7098 Cr | +11.8% |
| EBIT | ₹4222 Cr | ₹3453 Cr | ₹792 Cr | ₹1332 Cr | — | -25.1% |
| PAT | ₹3113 Cr | ₹2647 Cr | ₹506 Cr | ₹907 Cr | ₹3486 Cr | +2.9% |
| EPS (diluted) | ₹53.13 | ₹45.19 | ₹8.64 | ₹15.51 | — | -26.5% |
| CFO | ₹2994 Cr | ₹5016 Cr | ₹2387 Cr | ₹2435 Cr | ₹3925 Cr | +7.0% |
| CapEx | — | — | — | — | ₹-2520 Cr | — |
| FCF | — | — | — | — | ₹1405 Cr | +0.0% |
| Total Assets | — | ₹33.9K Cr | ₹39.9K Cr | ₹45.1K Cr | ₹49.8K Cr | +10.1% |
| Total Debt | — | — | ₹4243 Cr | ₹4180 Cr | ₹8263 Cr | +18.1% |
| Shareholders' Equity | — | — | ₹26.8K Cr | ₹29.8K Cr | ₹32.6K Cr | +5.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AUROPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| MANKIND MANKIND | — | — | Pending | 13.7% | — |
| ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
| ALKEM ALKEM | — | — | Pending | 17.4% | — |
| CIPLA CIPLA | — | — | Pending | 16.9% | 22.1× |
| GLENMARK GLENMARK | — | — | Pending | 11.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
20 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹20.50/sh
Last payout
2025-08-08
₹4.00
Peak payout
₹4.50
Trailing yield
0.29%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Aurobindo Pharma Limited has a current price of 1376.00 and a fair value of 1875.02, with a MoS of 36.3% and ROCE of 15.7%. Its ROE is 10...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AUROPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AUROPHARMA →
Compare
Head-to-head with peers
Compare AUROPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AUROPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.